

RECEIVED  
CENTRAL FAX CENTER

MAR 24 2006

**FAX TRANSMISSION****BEST AVAILABLE COPY****DATE:** March 24, 2006**PTO IDENTIFIER:** Application Number 10/001945-Conf. #9920  
Patent Number  
**Inventor:** Gary L. OLSON et al.**MESSAGE TO:** US Patent and Trademark Office**FAX NUMBER:** (571) 273-8300**FROM:** LAHIVE & COCKFIELD, LLP  
Maria Laccotripe Zacharakis, Ph.D., J.D.**PHONE:** (617) 227-7400**Attorney Dkt. #:** PPI-106CP2**PAGES (Including Cover Sheet):** 13**CONTENTS:** Request for Acknowledgement of Previously Submitted Information Disclosure Statement (2 pages)  
Certificate of Transmission (1 page)  
Appendix A (8 pages)  
Appendix B (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 227-7400 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

**LAHIVE & COCKFIELD, LLP**  
28 State Street, Boston, Massachusetts 02109  
Telephone: (617) 227-7400 Facsimile: (617) 742-4214

MAR 24 2006

PTO/SB/97 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031

U. S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/001945

Attorney Docket No.: PPI-106CP2

**BEST AVAILABLE COPY****Certificate of Transmission under 37 CFR 1.8**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on March 24, 2006  
Date



Signature

Maria Laccotripe Zacharakis, Ph.D., J.D.

Typed or printed name of person signing Certificate

56,266

Registration Number, if applicable

(617) 227-7400

Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Request for Acknowledgement of Previously Submitted Information  
Disclosure Statement (2 pages)  
Appendix A (8 pages)  
Appendix B (1 page)

RECEIVED  
CENTRAL FAX CENTER

MAR 24 2006

Docket No.: PPI-106CP2  
(PATENT)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (871) 273-8300 at Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 24, 2006

Signature: 

(Maria Laodotripe Zacharakis, Ph.D., J.D.)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Gary L. Olson *et al.*

Application No.: 10/001945

Group Art Unit: 1654

Filed: November 1, 2001

Examiner: J. E. Russel

For: THERAPEUTIC AGENTS AND METHODS OF  
USE THEREOF FOR THE MODULATION OF  
ANGIOGENESIS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

BEST AVAILABLE COPY

**REQUEST FOR ACKNOWLEDGEMENT OF PREVIOUSLY SUBMITTED  
INFORMATION DISCLOSURE STATEMENT (IDS)**

Dear Sir:

During a routine review of the file associated with the payment of the Issue Fee for the above-identified application, Applicants noticed that form PTO/1449, submitted with the Information Disclosure Statement (IDS) filed on March 25, 2003 in the above-identified application, has not yet been initialed by the Examiner and returned to Applicants.

As evidenced by Appendix A, submitted herewith, the IDS and its accompanying documents (PTO Form 1449 and Transmittal Letter) were filed on March 25, 2003. These documents were received by the U.S. Patent and Trademark Office on March 31, 2003, as confirmed by the return receipt postcard (a copy of which is attached herewith as Appendix B).

Moreover, as indicated on the IDS filed on March 25, 2003, all references listed on the PTO Form 1449 filed on March 25, 2003 were previously cited by or submitted to the Office in

Application No.: 10/001945

Docket No.: PPI-106CP2

connection with U.S. patent application Serial No. 09/972,772, filed October 5, 2001 (Atty. Docket No. PPI-106CP) and U.S. patent application Serial No. 09/704,251, filed November 1, 2000 (Attorney Docket No. PPI-106) to which the present application claims priority and which were also examined by Examiner Russell.

Therefore, Applicants respectfully request that the Examiner initial the Form PTO-1449 originally submitted on March 25, 2003 (a copy of which is enclosed herewith – 3 pages), and return a copy of the initialed form to Applicants to signify that the aforementioned references have been considered and made of record in the present application.

If there are any remaining issues, the Examiner is invited to call the undersigned at (617) 227-7400.

Dated: March 24, 2006

Respectfully submitted,

By 

Maria Laccotripe Zacharakis, Ph.D., J.D.

Registration No.: 56,266

LAHIVE &amp; COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

Attorney/Agent For Applicants

RECEIVED  
CENTRAL FAX CENTERIN THE UNITED STATES PATENT AND TRADEMARK OFFICE **MAR 24 2006**In re the application of: Olson, Gary L. *et al.*

Serial No.: 10/001945

Filed: November 1, 2001

For: *THERAPEUTIC AGENTS AND METHODS OF  
USE THEREOF FOR THE MODULATION OF  
ANGIOGENESIS*

Attorney Docket No.: PPI-106CP2

Group Art Unit: 1653

Examiner: Not Yet Assigned


Commissioner for Patents  
Washington, D.C. 20231Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

March 25, 2003

Date of Signature and of Mail Deposit

By:

  
Maria Laccotripe Zacharakis, Ph.D.  
Attorney for Applicants  
Limited Recognition Under 37 CFR  
§10.9(b)INFORMATION DISCLOSURE STATEMENT

Dear Sir:

For the Examiner's convenience in reviewing this application, Applicants submit a consolidated PTO Form 1449, listing all references cited during the prosecution of the parent applications. The present application is a continuation-in-part of U.S. Serial No. 09/972,772, filed October 5, 2001 (Atty. Docket No. PPI-106CP) which, in turn, is a continuation-in-part of U.S. patent application Serial No. 09/704,251, filed November 1, 2000 (Attorney Docket No. PPI-106). All references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to

Serial Number:10/004945

Page -2-


Group Art Unit: 1653

the Office in the prior applications, and, in accordance with 37 CFR §1.98(d), copies of the references are not enclosed but will be provided upon request.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

  
Maria Laccotripe Zacharakis, Ph.D.  
Limited Recognition Under 37 CFR §10.9(b)

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: March 25, 2003

GAD/MCL/MCA/ipc  
Enclosures

# LAHIVE & COCKFIELD LLP

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
GIULIO A. DECONTI, JR.  
ANN LAMPORT HAMMITTE  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DEANN FORAN SMITH  
PETER C. LAURO  
DEBRA J. MILASINOC, Ph.D.  
DAVID J. RICKERS  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER  
MEGAN E. WILLIAMS, Ph.D.

LISA M. DIROCCO  
HATHAWAY P. RUSSELL  
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.  
VINCENT P. LOCCISANO  
MERIDETH C. ARNOLD  
DANIELLE L. HERRITT  
ELIHOON LEE

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMAH LYNCH  
WILLIAM A. COCKFIELD, JR.  
SIBILEY P. REPPERT  
JEANNE M. DIORIGIO  
CYNTHIA L. KANIK, Ph.D.

PATENT AGENTS  
THEODORE R. WEST  
SHAYNE Y. HUFF, Ph.D.  
CYNTHIA M. BOROCOS  
PETER W. DINI, Ph.D.  
JONATHAN M. SPARKS, Ph.D.

TECHNICAL SPECIALISTS  
CATHERINE M. BISHOP  
JACOB G. WEINTRAUB  
CRISTIN E. HOWLEY, Ph.D.  
JILL ANN MELLO, Ph.D.

\* Admitted in TX only  
\*\* Admitted in CT only

MAR 24 2006

March 25, 2003

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Patent Application No.: 09/001945  
THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR THE  
MODULATION OF ANGIOGENESIS  
Inventor: Olson, Gary L. *et al.*  
Filed: November 1, 2001  
Our Ref. No.: PPI-106CP2

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. A Statement of Limited Recognition Under 37 CFR §10.9(b); and
4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any other necessary fees due in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

March 25, 2003

Date

Maria Laccotripe Zacharakis, Ph.D.,  
Limited Recognition Under 37 CFR §10.9(b)

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

Maria Laccotripe Zacharakis, Ph.D.  
Attorney for Applicants  
Limited Recognition Under 37 CFR §10.9(b)

# LAHIVE & COCKFIELD LLP

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahive.com

JOHN A. LAHIVE, JR. (1926-1987)  
THOMAS V. SMURZYNSKI  
RALPH A. LOREN  
GIULIO A. DECONTI, JR.  
ANN LAMPORT HAMMETT  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAKOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
OMANN FORAN SMITH  
PETER C. LAURO  
DEBRA J. MILASINIC, Ph.D.  
DAVID J. ROGERS  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER  
MEGAN E. WILLIAMS, Ph.D.

LISA M. DIROCCO  
KATHAWAY P. RUSSELL \*  
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.  
VINCENT P. LOCCISANO  
MERIDETH C. ARNOLD  
DANIELLE L. HERRITT  
EUNHOON LEE \*\*

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
WILLIAM A. BOOFIELD, JR.  
SISLEY P. REPPERT  
JEANNE M. DIGIORGIO  
CYNTHIA L. KAHN, Ph.D.

PATENT AGENTS  
THEODORE R. WEST  
SHAYNE Y. HUFF, Ph.D.  
CYNTHIA M. SOROS  
PETER W. DINI, Ph.D.  
JONATHAN M. SPARKS, Ph.D.

TECHNICAL SPECIALISTS  
CATHERINE M. BISHOP  
JACOB G. WEINTRAUB  
CRISTIN E. HOWLEY, Ph.D.  
JILL ANN MELLO, Ph.D.

\* Admitted in TX only  
\*\* Admitted in CT only

March 25, 2003

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Patent Application No.: 09/001945  
THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR THE  
MODULATION OF ANGIOGENESIS  
Inventor: Olson, Gary L. *et al.*  
Filed: November 1, 2001  
Our Ref. No.: PPI-106CP2

COPY

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. A Statement of Limited Recognition Under 37 CFR §10.9(b); and
4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any other necessary fees due in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

March 25, 2003

Date

Maria Laccotripe Zacharakis, Ph.D.,  
Limited Recognition Under 37 CFR §10.9(b)

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

Maria Laccotripe Zacharakis, Ph.D.  
Attorney for Applicants  
Limited Recognition Under 37 CFR §10.9(b)



Sheet 1 of 3

APPLICANT PAGE(S) OF FORM PTO-1449 REV 7-89	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY NO. <b>PPI-106CP2</b>	SERIAL NO. <b>10/001946</b>
<b>LIST OF PUBLICATIONS CITED BY APPLICANT</b> (Use several sheets if necessary)		APPLICANT <b>Olson, Gary L. et al.</b>	
		FILING DATE <b>November 1, 2001</b>	GROUP <b>1653</b>

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,135,919	8/92	Folkman et al.	514	50	
	A2	5,180,738	1/93	Kishimoto et al.	514	475	
	A3	5,290,807	3/94	Folkman et al.	514	475	
	A4	5,648,382	7/97	Billington et al.	514	475	
	A5	5,698,586	12/97	Kishimoto et al.	514	475	
	A6	5,767,293	6/98	Oku et al.	549	332	
	A7	5,789,405	8/98	Oku et al.	514	227.8	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A8	WO 9959986	11/99	PCT				
	A9	WO 9961432	12/99	PCT				
	A10	WO 0089472	11/00	PCT				

## OTHERS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A11	Denmeade SR, et al. "Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen." <i>Cancer Res.</i> 1998 Jun 15;58(12):2537-40
	A12	Griffith EC, et al. "Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2." <i>Proc Natl Acad Sci U S A.</i> 1998 Dec 22;95(26):15183-8
	A13	Griffith EC, et al. "Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin". <i>Chem Biol.</i> 1997 Jun;4(6):461-71
	A14	Han CK, et al. "Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2." <i>Bioorg Med Chem Lett.</i> 2000 Jan 3;10(1):39-43
	A15	Landquist, JK "Some Degradation Products of Fumagillin" <i>J. Chem. Soc.</i> 1956: 4237-4245
	A16	Tarbell et al. "Chemical Evidence For At Least Two Different Precursors To Cyclohexene Formed By Electron Irradiation Of Cyclohexane" 1960 Feb 20; 82:1005-1007
Examiner		Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 606; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		






**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE  
UNITED STATE PATENT AND TRADEMARK OFFICE**

**LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)**

Maria C. Laccotripe Zacharakis is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Lahive & Cockfield, LLP, to prepare and prosecute patent applications where the patent applicant is the client of Lahive & Cockfield, LLP, and the attorney or agent of record in the applications is a registered practitioner who is a member of the Lahive & Cockfield, LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Maria C. Laccotripe Zacharakis ceases to lawfully reside in the United States, (ii) Maria C. Laccotripe Zacharakis' employment with Lahive & Cockfield, LLP ceases or is terminated, or (iii) Maria C. Laccotripe Zacharakis ceases to remain or reside in the United States on an H-1 visa.



This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

**Expires: August 5, 2003**

  
Harry I. Moatz  
Director of Enrollment and Discipline

ATTENDING

BEST AVAILABLE COPY

NO POSTAGE STAMP NECESSARY  
POSTAGE HAS BEEN PREPAID BYLAHIVE & COCKFIELD, LLP  
28 STATE STREET  
BOSTON, MA 02109

02109-1786 97

Office No. PPI-106CP2THE "RECEIVED" STAMP OF THE PATENT AND TRADEMARK OFFICE  
IMPRINTED HEREON ACKNOWLEDGES THE FILING OF:

Description of Paper\*: Transmittal Letter (1 page, in duplicate), Information Disclosure Statement (2 pages), PTO Form 1449 (3 pages), and a Statement of Limited Recognition Under 37 CFR §10.9(b) (1 page) are enclosed along with this return postcard.

Title: *THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR THE MODULATION OF ANGIOGENESIS*Name of Applicants: Olson, Gary L. *et al.*

Serial No.: 10/001,945

Atty: GAD/AEM/MCL/MCA

Date: March 25, 2003

\*with Certificate of First Class Mailing

